NCPAD2 is a favorable predictor of prognostic and immunotherapeutic biomarker for multiple cancer types including lung cancer.
Linyuan FengYang YangZhenhua LinMinghua CuiAihua JinAili CuiPublished in: Genes and environment : the official journal of the Japanese Environmental Mutagen Society (2024)
It was found that NCAPD2 was overexpressed in pan-cancers, which was associated with poor outcomes. Importantly, NCAPD2 could be a diagnostic marker and an immune related biomarker for LUAD and LUSC.